WHEN Prima BioMed's chairman Lucy Turnbull and chief executive Martin Rogers rang the Nasdaq's opening bell in New York on Monday night celebrating its listing in the US, it produced a reaction they probably weren't expecting.
Since then the high-performing biotech's stock has fallen about 15 per cent. Possibly this is a portent of more to come. Prima is developing a treatment for ovarian cancer and at 22¢ its market cap is $256 million. This is hefty for a company that isn't forecast to make a profit for at least another four years (if it even does).
The clinical results Prima BioMed has come up with so far do not seem to support its share price rise from 2¢ or so in early 2009, to peak at 39¢ this time last year. The full results of its preliminary (phase 2) are due out in the next few months, but what we know so far is that the data from 21 patients "has not demonstrated statistically significant results" in the words of a report by Nomura Equity Research.
Prima is one of the new breed of "biologic" drugs, made from cell lines that are almost impossible to copy, rather than the simple chemical synthesis used to develop small-molecule drugs such as aspirin. Its CVac vaccine is designed to prevent the recurrence of ovarian cancer after surgery and chemotherapy. Dendritic cells are taken out of a woman's body and then "sensitised" to ovarian cancer and reinserted. When a woman's cells sense ovarian cancer these cells take it to the immune system and destroy the cells, in theory.
Advocates tout the performance of US biotech Dendreon, which has a similar "immunotherapy" for prostate cancer. Owing to supply issues its shares have halved in the past few months, but its market cap is still $US1.4 billion ($1.3 billion). The big difference between the two is approval. Prima has a long time in the wilderness before the final results of its crucial late-stage 800-patient trial. Also, we haven't heard a peep out of the big pharma.
Source: Fairfax, 23 April, 2012
Start Your 30 day free trial today
Do you want to get access to our weekly reports?
Leave your details and get an instant access.